MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Phase 2
Terminated
Conditions
Anemia
Cancer
Epoetin Alfa
First Posted Date
2006-03-23
Last Posted Date
2011-05-18
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
61
Registration Number
NCT00306267

Mode of Action of Topiramate in the Treatment of Obese Patients With and Without Type 2 Diabetes Mellitus

Completed
Conditions
Obesity
Diabetes Mellitus Type 2
Interventions
Other: No intervention
First Posted Date
2006-03-20
Last Posted Date
2012-11-28
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1145
Registration Number
NCT00304603

Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease

Phase 3
Completed
Conditions
Alzheimer Disease
First Posted Date
2006-03-20
Last Posted Date
2011-02-01
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
241
Registration Number
NCT00304629

A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives

Phase 3
Withdrawn
Conditions
Neural Tube Defects
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Nervous System Malformations
First Posted Date
2006-03-13
Last Posted Date
2016-09-20
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Registration Number
NCT00301587

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Psychotic Disorders
Interventions
First Posted Date
2006-03-07
Last Posted Date
2011-12-30
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
355
Registration Number
NCT00299702

A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder

Phase 3
Completed
Conditions
Bipolar Disorder
Mood Disorders
First Posted Date
2006-03-07
Last Posted Date
2011-06-09
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
473
Registration Number
NCT00299715

An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine

Completed
Conditions
Mild Cognitive Impairment
Interventions
Other: No intervention
First Posted Date
2006-02-28
Last Posted Date
2012-04-12
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1083
Registration Number
NCT00297414

A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache

Phase 4
Completed
Conditions
Migraine
Head Pain
Headache
First Posted Date
2006-02-28
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
375
Registration Number
NCT00297375
© Copyright 2025. All Rights Reserved by MedPath